Early-Onset Gastric Cancer
Conditions
Interventions
Early-onset gastric cancer group:NA
Late-onset gastric cancer group:NA
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, aged 18 years old or above and 75 years old or below. 2. Gastric cancer newly diagnosed and confirmed by histology. 3. No serious comorbidities that could lead to a survival period of less than 5 years. 4. Willing and able to comply with the study protocol and subsequent procedures during the research. 5. Provide written informed consent before entering the study, and the patient has been informed that they can withdraw from the study at any time during the research without any loss.
Exclusion criteria
Exclusion criteria: 1. Have previously received organ transplantation or non-autologous bone marrow or stem cell transplantation. 2. Those who have received cytotoxic chemotherapy, radiotherapy, interventional therapy, immunotherapy, surgical treatment or radical resection for the treatment of this gastric cancer and have any active malignancy within 2 years, except for the specific cancer being studied in this trial and locally recurrent cancers that have been cured (such as excised basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ). 3. Have received drugs with anti-tumor effects for other diseases within 30 days, such as methotrexate, cyclophosphamide, azathioprine, chlorambucil, etc. for immunorheumatic diseases, and tamoxifen for breast diseases. 4. Have received hormonal drug treatment (such as methylprednisolone, etc.) within the last 14 days. 5. Have received anti-infection treatment within the last 14 days. 6. Severe chronic or active infections that require systemic antibacterial, antifungal or antiviral treatment, including tuberculosis, HIV infection, etc. 7. Patients with untreated chronic hepatitis B or chronic HBV carriers with hepatitis B virus (HBV) DNA exceeding 500 IU/mL, or patients with positive hepatitis C virus (HCV) RNA should be excluded. Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA < 500 IU/mL), and cured hepatitis C patients can be enrolled. 8. Have received live vaccines within 4 weeks before enrollment. (Note: Seasonal influenza vaccines are usually inactivated vaccines and are allowed to be used. Vaccines used intranasally are live vaccines and are not allowed to be used.); 9. Have undergone major surgery within the last 28 days, unless the surgery is minimally invasive (such as laparoscopic exploration or invasive procedures like peripherally inserted central catheter [PICC]). 10. Are taking warfarin or anti-platelet drugs for anticoagulation therapy (on the day of blood collection). 11. Have other malignancies or multiple primary tumors simultaneously.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative Complications; | — |
Secondary
| Measure | Time frame |
|---|---|
| Psychoneuroimmunological Correlation;Overall Survival (OS);Disease-Free Survival (DFS); | — |
Countries
China
Contacts
Public ContactWang Xuefei
Zhongshan Hospital, Fudan University
Outcome results
None listed